- Abbott Laboratories (NYSE:ABT) is expanding further into health technology with new diagnostics and wearables, including its Lingo biomarker device.
- The company is increasing R&D spending on cardiovascular diagnostics aimed at earlier detection of heart conditions.
- This shift highlights Abbott’s focus on digital health solutions beyond recent guidance, acquisitions, and short term market pressures.
Abbott Laboratories, trading at $87.41, is drawing attention for company moves that do not show up directly in recent share price swings. The stock is up 3.5% over the past week, but longer term returns are weaker, with the share price down 29.6% year to date and down 32.1% over the past year. In that context, the renewed push into diagnostics and wearables gives investors a different angle to assess NYSE:ABT.
The expansion of devices like Lingo and increased cardiovascular R&D place Abbott more squarely in digital health and data driven care. For investors, the key question is how this effort could reshape the company’s mix of revenue drivers over time and influence how the stock is viewed relative to other health tech peers.
Stay updated on the most important news stories for Abbott Laboratories by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Abbott Laboratories.
We've flagged 2 risks for Abbott Laboratories. See which could impact your investment.
For Abbott, expanding into diagnostics wearables and cardiac-focused tools is about shifting more of its business toward data rich, recurring-use devices. Products like the Lingo biomarker device and new cardiovascular diagnostics sit close to the patient and clinician workflow, which can deepen relationships and create follow-on demand across Abbott’s broader device and testing portfolio. This push also lines up with wider efforts in heart rhythm and arrhythmia care, where the global market for conditions such as paroxysmal supraventricular tachycardia is seeing more attention on early detection and long term monitoring. Investors weighing the recent Exact Sciences acquisition and softer sentiment around medical devices now have a clearer picture of how Abbott is trying to reposition itself. The trade off is that higher R&D and software investment can pressure margins if adoption is slower than expected or if competitors such as Medtronic, Boston Scientific and Dexcom move faster with their own digital health ecosystems.
How This Fits Into The Abbott Laboratories Narrative
- This news lines up with the narrative’s focus on medical technologies in areas like structural heart and rhythm management, as Lingo and cardiovascular diagnostics support a broader push into chronic disease monitoring.
- Higher spend on digital health platforms and wearables could weigh on near term profitability, which challenges the narrative’s emphasis on margin improvement if revenue contribution lags.
- The specific move into consumer facing biomarker wearables is not fully captured in the narrative’s emphasis on FreeStyle Libre and traditional devices, so the potential impact of this category may be underrepresented.
Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Abbott Laboratories to help decide what it's worth to you.
The Risks and Rewards Investors Should Consider
- ⚠️ Executing on a larger digital health roadmap requires sustained R&D and software investment, which could limit profit margin recovery if new devices take time to scale.
- ⚠️ Competition in wearables and cardiac diagnostics from players such as Medtronic, Boston Scientific and Dexcom may pressure pricing and reduce the return on Abbott’s new products.
- 🎁 A wider suite of diagnostics and wearables can deepen Abbott’s role in chronic cardiovascular care, which analysts already view as an important driver of earnings growth.
- 🎁 Success in early detection tools could strengthen customer loyalty across hospitals and clinics, supporting the case that the stock offers good value relative to its earnings potential.
What To Watch Going Forward
From here, pay attention to how quickly new diagnostics and wearables move from launch to regular clinical use, especially in cardiology. Adoption by large hospital systems, reimbursement decisions, and physician feedback will be key indicators of whether Lingo and related platforms can become meaningful contributors rather than niche offerings. It is also worth tracking how Abbott balances R&D spending across digital health and its existing franchises, given prior concerns around earnings dilution and softer guidance. Any commentary on integration between these devices and broader data platforms will help clarify whether Abbott can build a cohesive ecosystem that stands out next to larger device peers.
To ensure you're always in the loop on how the latest news impacts the investment narrative for Abbott Laboratories, head to the community page for Abbott Laboratories to never miss an update on the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com